
Opus Genetics, Inc. (NASDAQ:IRD – Free Report) – Analysts at Brookline Capital Markets lifted their FY2026 EPS estimates for shares of Opus Genetics in a report released on Thursday, November 12th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($0.42) for the year, up from their prior estimate of ($0.87). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.70) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ FY2027 earnings at ($0.62) EPS.
Several other research analysts have also recently issued reports on IRD. Zacks Research raised Opus Genetics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Citizens Jmp reiterated a “market outperform” rating and issued a $17.00 price objective on shares of Opus Genetics in a report on Friday, October 16th. HC Wainwright raised their target price on Opus Genetics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, November 11th. Wedbush boosted their target price on Opus Genetics from $10.00 to $13.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Opus Genetics has an average rating of “Moderate Buy” and an average target price of $13.29.
Get Our Latest Stock Analysis on IRD
Opus Genetics Stock Up 1.5%
Opus Genetics stock opened at $4.04 on Tuesday. Opus Genetics has a 1-year low of $1.70 and a 1-year high of $7.07. The company has a debt-to-equity ratio of 0.90, a current ratio of 9.65 and a quick ratio of 12.19. The stock has a market cap of $390.48 million, a PE ratio of -2.59 and a beta of 0.80. The stock’s fifty day moving average is $4.47 and its two-hundred day moving average is $4.24.
Opus Genetics (NASDAQ:IRD – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.31). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.55 million.
Insider Activity at Opus Genetics
In other Opus Genetics news, President Benjamin R. Yerxa sold 33,189 shares of the firm’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.54, for a total transaction of $117,489.06. Following the transaction, the president owned 670,917 shares of the company’s stock, valued at approximately $2,375,046.18. This trade represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of Opus Genetics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total value of $2,757,760.00. Following the sale, the director owned 3,236,171 shares in the company, valued at $16,051,408.16. This trade represents a 14.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 673,805 shares of company stock valued at $3,213,582 over the last quarter. 11.70% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Stoneridge Investment Partners LLC purchased a new stake in Opus Genetics in the second quarter valued at approximately $47,000. Engineers Gate Manager LP purchased a new position in shares of Opus Genetics during the second quarter worth approximately $50,000. Sanders Morris Harris LLC purchased a new position in shares of Opus Genetics during the third quarter worth approximately $58,000. StoneRidge PMG Advisors LLC purchased a new position in shares of Opus Genetics during the third quarter worth approximately $61,000. Finally, State of Wyoming acquired a new position in shares of Opus Genetics in the 2nd quarter valued at $65,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.
See Also
- Five stocks we like better than Opus Genetics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
